Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)

Autor: Toby M. Maher, Arthur R. Kang’ombe, Allan Listanco, Azeem Saleem, Richard P. Marshall, Joaquim Ramada-Magalhaes, Gisli Jenkins, Maria Costa, Christopher Coello, Pauline T. Lukey, James Davies, Sara Moz, Stuart Kendrick, Roger N. Gunn, Nadia Garman, Christine A. Parker, William A. Fahy, Mayca Onega, Jan Passchier, Frederick J. Wilson
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Integrins
alpha v beta 6 integrin
Gastroenterology
030218 nuclear medicine & medical imaging
Idiopathic pulmonary fibrosis
0302 clinical medicine
Fibrosis
RHEUMATOLOGY/EUROPEAN LEAGUE
Positron Emission Tomography Computed Tomography
Pulmonary fibrosis
BINDING
CLASSIFICATION CRITERIA
[18F]FB-A20FMDV2 PET/CT
Respiratory system
Lung
Volume of distribution
medicine.diagnostic_test
Radiology
Nuclear Medicine & Medical Imaging
General Medicine
Connective tissue disease
CANCER
Nuclear Medicine & Medical Imaging
Original Article
αvβ6 integrin
Life Sciences & Biomedicine
CT
EXPRESSION
medicine.medical_specialty
High-resolution computed tomography
MOUTH-DISEASE-VIRUS
0299 Other Physical Sciences
PROGNOSTIC BIOMARKER
AMERICAN-COLLEGE
DIAGNOSIS
Clinical study
03 medical and health sciences
Antigens
Neoplasm
Internal medicine
medicine
[F-18]FB-A20FMDV2 PET
Humans
Radiology
Nuclear Medicine and imaging
Science & Technology
business.industry
1103 Clinical Sciences
Biomarker
medicine.disease
030104 developmental biology
PET
Positron-Emission Tomography
INTEGRIN-ALPHA(V)BETA(6)
business
Emission computed tomography
Zdroj: European Journal of Nuclear Medicine and Molecular Imaging
ISSN: 1619-7089
1619-7070
Popis: PurposeThe RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [18F]FB-A20FMDV2 PET ligand.Methods[18F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (VT) were used to quantify αvβ6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between αvβ6 expression and the distribution of fibrosis on high resolution computed tomography was conducted.ResultsA total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled.VTand SUV of [18F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric meanVT(95% CI) was 0.88 (0.60, 1.29) mL/cm3for healthy subjects, and 1.40 (1.22, 1.61) mL/cm3for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthyVTratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [18F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [18F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [18F]FB-A20FMDV2 was safe and well tolerated.ConclusionsLung uptake of [18F]FB-A20FMDV2, a measure of expression of the integrin αvβ6, was markedly increased in subjects with PF compared with healthy subjects.
Databáze: OpenAIRE
Externí odkaz: